January 22, 2025 – Talk Bio

Actionable Insights Powered by AI

Trump Revokes Biden’s Executive Order on AI Safety and Trustworthiness

3 months ago talkbio0Tagged Administration occupational activities, AI safety, Aortic Valve Insufficiency, Artificial (qualifier value), Biden Executive Order, governance, Regulation, Transplant Registry Unified Management Program

AI Safety, Biden Executive Order, Trump Administration, Artificial Intelligence Governance, AI Regulation

Leo Pharma Acquires EU Rights to Loqtorzi, Boosting Marketing Efforts for PD-1 Inhibitor

3 months ago talkbio0Tagged Biosciences, EU, Inhibitor, Junshi, Loqtorzi, Nasopharyngeal carcinoma, PDCD1 gene, Pharma, rights

Loqtorzi, PD-1 Inhibitor, Nasopharyngeal Carcinoma, EU Rights, Leo Pharma, Junshi Biosciences, Marketing Efforts

J&J’s Spravato Surpasses $1 Billion in Revenue for 2024

3 months ago talkbio0Tagged 2024, J&J, Mental Depression, Nasal Spray, Spravato

J&J, Spravato, revenue, 2024, depression treatment, nasal spray

ArriVent Expands ADC Pipeline with Exclusive License for MRG007 from Lepu Biopharma

3 months ago talkbio0Tagged Antibody-Drug Conjugates, ArriVent, Biopharma, Lepu Biopharma, Malignant neoplasm of gastrointestinal tract, MRG007

ArriVent BioPharma, Lepu Biopharma, MRG007, Antibody Drug Conjugate (ADC), Gastrointestinal Cancers, Exclusive License Agreement

HHS Awards Moderna $590 Million to Expedite Bird Flu Vaccine Development

3 months ago talkbio0Tagged Aves, CHARGE Syndrome, Moderna, mRNA Vaccine, pandemic preparedness, Vaccines

Moderna, HHS, Bird Flu Vaccine, Avian Influenza, mRNA Vaccine, Pandemic Preparedness

FDA Places Clinical Hold on Atara Biotherapeutics’ EBVALLO and ATA3219 Due to Manufacturing Compliance Issues

3 months ago talkbio0Tagged allogeneic T-cell therapies, Atara Biotherapeutics, Biomechanical compliance, Ebvallo, Epstein-Barr virus, GMP, Guanosine Monophosphate, Lupus Erythematosus, Systemic, Manufacturing, Post-transplant lymphoproliferative disorder, Study on Hold, United States Food and Drug Administration

Atara Biotherapeutics, FDA clinical hold, EBVALLO, ATA3219, allogeneic T-cell therapies, manufacturing compliance issues, GMP compliance, Epstein-Barr virus, post-transplant lymphoproliferative disease, non-Hodgkin’s lymphoma, systemic lupus erythematosus.